Logo image of ANIP

ANI PHARMACEUTICALS INC (ANIP) Stock Fundamental Analysis

NASDAQ:ANIP - Nasdaq - US00182C1036 - Common Stock - Currency: USD

69.96  +1.01 (+1.46%)

Fundamental Rating

5

Taking everything into account, ANIP scores 5 out of 10 in our fundamental rating. ANIP was compared to 198 industry peers in the Pharmaceuticals industry. ANIP has only an average score on both its financial health and profitability. ANIP is evaluated to be cheap and growing strongly. This does not happen too often!


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year ANIP was profitable.
ANIP had a positive operating cash flow in the past year.
ANIP had negative earnings in 4 of the past 5 years.
Of the past 5 years ANIP 4 years had a positive operating cash flow.
ANIP Yearly Net Income VS EBIT VS OCF VS FCFANIP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

1.2 Ratios

ANIP's Return On Assets of -0.30% is amongst the best of the industry. ANIP outperforms 81.82% of its industry peers.
ANIP's Return On Equity of -0.90% is amongst the best of the industry. ANIP outperforms 82.32% of its industry peers.
ANIP has a Return On Invested Capital of 1.29%. This is in the better half of the industry: ANIP outperforms 76.77% of its industry peers.
Industry RankSector Rank
ROA -0.3%
ROE -0.9%
ROIC 1.29%
ROA(3y)-2.12%
ROA(5y)-3.36%
ROE(3y)-5.31%
ROE(5y)-7.87%
ROIC(3y)N/A
ROIC(5y)N/A
ANIP Yearly ROA, ROE, ROICANIP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 -5 10 -10

1.3 Margins

Looking at the Operating Margin, with a value of 2.37%, ANIP is in the better half of the industry, outperforming 76.77% of the companies in the same industry.
In the last couple of years the Operating Margin of ANIP has declined.
With a decent Gross Margin value of 60.18%, ANIP is doing good in the industry, outperforming 67.68% of the companies in the same industry.
In the last couple of years the Gross Margin of ANIP has declined.
Industry RankSector Rank
OM 2.37%
PM (TTM) N/A
GM 60.18%
OM growth 3YN/A
OM growth 5Y-47.18%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.51%
GM growth 5Y-3.12%
ANIP Yearly Profit, Operating, Gross MarginsANIP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

More info and screens

5

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so ANIP is destroying value.
ANIP has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, ANIP has more shares outstanding
The debt/assets ratio for ANIP is higher compared to a year ago.
ANIP Yearly Shares OutstandingANIP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
ANIP Yearly Total Debt VS Total AssetsANIP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

ANIP has an Altman-Z score of 1.88. This is not the best score and indicates that ANIP is in the grey zone with still only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 1.88, ANIP is in the better half of the industry, outperforming 67.68% of the companies in the same industry.
ANIP has a debt to FCF ratio of 13.06. This is a negative value and a sign of low solvency as ANIP would need 13.06 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 13.06, ANIP belongs to the top of the industry, outperforming 80.30% of the companies in the same industry.
A Debt/Equity ratio of 1.43 is on the high side and indicates that ANIP has dependencies on debt financing.
ANIP's Debt to Equity ratio of 1.43 is on the low side compared to the rest of the industry. ANIP is outperformed by 72.73% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.43
Debt/FCF 13.06
Altman-Z 1.88
ROIC/WACC0.14
WACC9.33%
ANIP Yearly LT Debt VS Equity VS FCFANIP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

ANIP has a Current Ratio of 2.72. This indicates that ANIP is financially healthy and has no problem in meeting its short term obligations.
ANIP has a Current ratio (2.72) which is comparable to the rest of the industry.
ANIP has a Quick Ratio of 2.02. This indicates that ANIP is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of ANIP (2.02) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.72
Quick Ratio 2.02
ANIP Yearly Current Assets VS Current LiabilitesANIP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

7

3. Growth

3.1 Past

ANIP shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 10.17%, which is quite good.
The Earnings Per Share has been growing slightly by 0.59% on average over the past years.
Looking at the last year, ANIP shows a very strong growth in Revenue. The Revenue has grown by 54.45%.
ANIP shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 24.37% yearly.
EPS 1Y (TTM)10.17%
EPS 3Y16.84%
EPS 5Y0.59%
EPS Q2Q%63%
Revenue 1Y (TTM)54.45%
Revenue growth 3Y41.66%
Revenue growth 5Y24.37%
Sales Q2Q%44.75%

3.2 Future

Based on estimates for the next years, ANIP will show a quite strong growth in Earnings Per Share. The EPS will grow by 12.43% on average per year.
Based on estimates for the next years, ANIP will show a quite strong growth in Revenue. The Revenue will grow by 9.67% on average per year.
EPS Next Y23.99%
EPS Next 2Y16.95%
EPS Next 3Y16.54%
EPS Next 5Y12.43%
Revenue Next Year28.29%
Revenue Next 2Y17.55%
Revenue Next 3Y13.75%
Revenue Next 5Y9.67%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
ANIP Yearly Revenue VS EstimatesANIP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
ANIP Yearly EPS VS EstimatesANIP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2 4 6 8 10

More info and screens

7

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 13.45, ANIP is valued correctly.
Based on the Price/Earnings ratio, ANIP is valued cheaply inside the industry as 87.37% of the companies are valued more expensively.
ANIP is valuated cheaply when we compare the Price/Earnings ratio to 28.33, which is the current average of the S&P500 Index.
ANIP is valuated reasonably with a Price/Forward Earnings ratio of 10.85.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ANIP indicates a rather cheap valuation: ANIP is cheaper than 86.87% of the companies listed in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.37, ANIP is valued a bit cheaper.
Industry RankSector Rank
PE 13.45
Fwd PE 10.85
ANIP Price Earnings VS Forward Price EarningsANIP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

ANIP's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. ANIP is cheaper than 78.79% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, ANIP is valued cheaply inside the industry as 80.30% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 31.58
EV/EBITDA 22.84
ANIP Per share dataANIP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ANIP's earnings are expected to grow with 16.54% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.56
PEG (5Y)22.91
EPS Next 2Y16.95%
EPS Next 3Y16.54%

More info and screens

0

5. Dividend

5.1 Amount

ANIP does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ANI PHARMACEUTICALS INC

NASDAQ:ANIP (4/23/2025, 11:12:42 AM)

69.96

+1.01 (+1.46%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-28 2025-02-28/bmo
Earnings (Next)05-09 2025-05-09/bmo
Inst Owners95.29%
Inst Owner Change-0.73%
Ins Owners6.75%
Ins Owner Change7.23%
Market Cap1.51B
Analysts84.29
Price Target82.62 (18.1%)
Short Float %14.5%
Short Ratio10.58
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0.08
Dividend Growth(5Y)N/A
DP-42.26%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.17%
Min EPS beat(2)11.36%
Max EPS beat(2)20.97%
EPS beat(4)4
Avg EPS beat(4)14.17%
Min EPS beat(4)5.26%
Max EPS beat(4)20.97%
EPS beat(8)8
Avg EPS beat(8)53.7%
EPS beat(12)10
Avg EPS beat(12)15.5%
EPS beat(16)12
Avg EPS beat(16)14.9%
Revenue beat(2)2
Avg Revenue beat(2)3.64%
Min Revenue beat(2)0.74%
Max Revenue beat(2)6.54%
Revenue beat(4)4
Avg Revenue beat(4)4.77%
Min Revenue beat(4)0.74%
Max Revenue beat(4)6.91%
Revenue beat(8)8
Avg Revenue beat(8)10.16%
Revenue beat(12)11
Avg Revenue beat(12)7.61%
Revenue beat(16)14
Avg Revenue beat(16)7.1%
PT rev (1m)2.32%
PT rev (3m)7.14%
EPS NQ rev (1m)2.27%
EPS NQ rev (3m)23.31%
EPS NY rev (1m)13.73%
EPS NY rev (3m)15.63%
Revenue NQ rev (1m)0.57%
Revenue NQ rev (3m)9.46%
Revenue NY rev (1m)0.65%
Revenue NY rev (3m)6.75%
Valuation
Industry RankSector Rank
PE 13.45
Fwd PE 10.85
P/S 2.01
P/FCF 31.58
P/OCF 23.57
P/B 3.52
P/tB N/A
EV/EBITDA 22.84
EPS(TTM)5.2
EY7.43%
EPS(NY)6.45
Fwd EY9.22%
FCF(TTM)2.22
FCFY3.17%
OCF(TTM)2.97
OCFY4.24%
SpS34.85
BVpS19.87
TBVpS-8.03
PEG (NY)0.56
PEG (5Y)22.91
Profitability
Industry RankSector Rank
ROA -0.3%
ROE -0.9%
ROCE 1.63%
ROIC 1.29%
ROICexc 1.5%
ROICexgc 4.17%
OM 2.37%
PM (TTM) N/A
GM 60.18%
FCFM 6.36%
ROA(3y)-2.12%
ROA(5y)-3.36%
ROE(3y)-5.31%
ROE(5y)-7.87%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5Y-44.22%
ROICexc growth 3YN/A
ROICexc growth 5Y-46.62%
OM growth 3YN/A
OM growth 5Y-47.18%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.51%
GM growth 5Y-3.12%
F-Score4
Asset Turnover0.59
Health
Industry RankSector Rank
Debt/Equity 1.43
Debt/FCF 13.06
Debt/EBITDA 7.19
Cap/Depr 23.97%
Cap/Sales 2.16%
Interest Coverage 0.73
Cash Conversion 74.84%
Profit Quality N/A
Current Ratio 2.72
Quick Ratio 2.02
Altman-Z 1.88
F-Score4
WACC9.33%
ROIC/WACC0.14
Cap/Depr(3y)17.9%
Cap/Depr(5y)14.57%
Cap/Sales(3y)2.42%
Cap/Sales(5y)2.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)10.17%
EPS 3Y16.84%
EPS 5Y0.59%
EPS Q2Q%63%
EPS Next Y23.99%
EPS Next 2Y16.95%
EPS Next 3Y16.54%
EPS Next 5Y12.43%
Revenue 1Y (TTM)54.45%
Revenue growth 3Y41.66%
Revenue growth 5Y24.37%
Sales Q2Q%44.75%
Revenue Next Year28.29%
Revenue Next 2Y17.55%
Revenue Next 3Y13.75%
Revenue Next 5Y9.67%
EBIT growth 1Y-62.93%
EBIT growth 3YN/A
EBIT growth 5Y-34.31%
EBIT Next Year29.93%
EBIT Next 3Y18.6%
EBIT Next 5Y13.48%
FCF growth 1Y-56.6%
FCF growth 3Y297.63%
FCF growth 5Y4.15%
OCF growth 1Y-46.19%
OCF growth 3Y168.16%
OCF growth 5Y7.01%